Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 145 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Period Pain Clear all
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 11:13 AM EDT
Suspended Phase 3 Interventional

Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

NCT04681027
View directory record Official record
Conditions
Chronic Pain, Postsurgical Pain
Interventions
Oxymorphone hydrochloride (HCl)
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
7 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Orange, California • New Orleans, Louisiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Jul 23, 2026, 11:13 AM EDT
Not yet recruiting Phase 1 Interventional

Vaginal Sildenafil for Primary Dysmenorrhea

NCT07508358
View directory record Official record
Conditions
Dysmenorrhea, Menstrual Pain
Interventions
Sildenafil citrate vaginal suppository, Placebo vaginal suppository
Drug
Lead sponsor
Kevin Hellman
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Women's Health Study: From Adolescence to Adulthood

NCT01738204
View directory record Official record
Conditions
Pelvic Pain, Endometriosis, Dysmenorrhea, Infertility
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 60 Years · Female only
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery

NCT00877799
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain

NCT00196365
View directory record Official record
Conditions
Dysmenorrhea
Interventions
levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets, levonorgestrel/EE 0.15/0.03 mg tablets and placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 23, 2026, 11:13 AM EDT
Terminated Phase 2 Interventional Results available

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

NCT01116440
View directory record Official record
Conditions
Pelvic Pain Associated With Refractory Endometriosis
Interventions
BGS649, Placebo
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
42
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 11:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Objective Outcomes With the Use of an Activity Tracker During the Trial Period of Spinal Cord Stimulation

NCT02641223
View directory record Official record
Conditions
Post-laminectomy Syndrome, Axial Back Pain
Interventions
spinal cord stimulator
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 11:13 AM EDT
Recruiting Phase 4 Interventional

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

NCT06861920
View directory record Official record
Conditions
Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions
Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional

Clinical Trial to Examine the Pain Relief of PH-797804 Alone Or With Naproxen in Subjects With Osteoarthritis of the Knee

NCT01102660
View directory record Official record
Conditions
Osteoarthritis
Interventions
PH-797804, Placebo, Naproxen, Naproxen + PH-797804
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Paramount, California • Spring Valley, California • Valley Village, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

NCT04335591
View directory record Official record
Conditions
Endometriosis
Interventions
75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo capsule to match Add-back capsule
Drug
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Dothan, Alabama • Homestead, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 23, 2026, 11:13 AM EDT
Not listed Phase 2 Interventional

Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea

NCT04091789
View directory record Official record
Conditions
Dysmenorrhea, Headache, Migraine, Fatigue, Nausea, Mood Disturbance
Interventions
Pure Femme Tablets
Drug
Lead sponsor
Pure Green
Industry
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sterling Heights, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

NCT00763321
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
ABT-712, Placebo
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
21 Years to 75 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
31
States / cities
Huntsville, Alabama • Burbank, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Bunionectomy Study for Postoperative Analgesia (EPOCH 1)

NCT03295721
View directory record Official record
Conditions
Postoperative Pain
Interventions
HTX-011, Saline Placebo, Bupivacaine HCl, Luer-lock applicator, Vial access device
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional Results available

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
XPF-002, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Jonesboro, Arkansas • Lomita, California • Westlake Village, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Not applicable Interventional

Ultrasound Evaluation Versus Direct Measurement of Uterine Cavity Length

NCT04425577
View directory record Official record
Conditions
Dysmenorrhea, Heavy Menstrual Bleeding, Contraception
Interventions
Transabdominal Ultrasound
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
12 Years to 22 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jul 23, 2026, 11:13 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain

NCT03343067
View directory record Official record
Conditions
Endometriosis
Interventions
elagolix, estradiol/norethindrone acetate (E2/NETA)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Anniston, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets

NCT01922739
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 2 Interventional

VA111913 Dysmenorrhoea Efficacy and Safety Proof of Concept

NCT00963053
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
VA111913 TS and placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Peoria, Arizona • Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect on Primary Dysmenorrhea

NCT00909857
View directory record Official record
Conditions
Primary Dysmenorrhea
Interventions
Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ethinyl estradiol, Levonorgestrel (Miranova), Placebo Match to SH T00658ID, Placebo Match to SH D593B
Drug
Lead sponsor
Bayer
Industry
Eligibility
14 Years to 50 Years · Female only
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Tucson, Arizona • San Diego, California • Hialeah, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period.

NCT01400139
View directory record Official record
Conditions
Chronic Nonmalignant and Nonneuropathic Pain
Interventions
Hydrocodone bitartrate q24h film-coated tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Jul 23, 2026, 11:13 AM EDT
Not listed Phase 3 Interventional

Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

NCT02858453
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
Interventions
AQX-1125 100 mg, AQX-1125 200 mg, Placebo
Drug
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
56
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Jul 23, 2026, 11:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigation Into the Efficacy of a Botanical Supplement to Provide Period Relief

NCT05845970
View directory record Official record
Conditions
Menstrual Pain, Premenstrual Syndrome
Interventions
Pamprin Botanicals, Pamprin Botanicals + Pamprin Menstrual Pain Relief
Other · Combination Product
Lead sponsor
Focus Consumer Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 23, 2026, 11:13 AM EDT